Lysine methyltransferases SMYD2 and SMYD3 are involved in the epigenetic regulation of cell differentiation and functioning. Overexpression and deregulation of these enzymes have been correlated to the insurgence and progression of different tumors, making them promising molecular targets in cancer therapy even if their role in tumors is not yet fully understood. In this light, selective small-molecule inhibitors are required to fully understand and validate these enzymes, as this is a prerequisite for the development of successful targeted therapeutic strategies. The present review gives a systematic overview of the chemical probes developed to selectively target SMYD2 and SMYD3, with particular focus on the structural features important for high inhibitory activity, on the mode of inhibition and on the efficacy in cell-based and in in vivo models.

Fabini E., Manoni E., Ferroni C., Del Rio A., Bartolini M. (2019). Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: Current trends. FUTURE MEDICINAL CHEMISTRY, 11(8), 901-921 [10.4155/fmc-2018-0380].

Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: Current trends

Fabini E.;Bartolini M.
2019

Abstract

Lysine methyltransferases SMYD2 and SMYD3 are involved in the epigenetic regulation of cell differentiation and functioning. Overexpression and deregulation of these enzymes have been correlated to the insurgence and progression of different tumors, making them promising molecular targets in cancer therapy even if their role in tumors is not yet fully understood. In this light, selective small-molecule inhibitors are required to fully understand and validate these enzymes, as this is a prerequisite for the development of successful targeted therapeutic strategies. The present review gives a systematic overview of the chemical probes developed to selectively target SMYD2 and SMYD3, with particular focus on the structural features important for high inhibitory activity, on the mode of inhibition and on the efficacy in cell-based and in in vivo models.
2019
Fabini E., Manoni E., Ferroni C., Del Rio A., Bartolini M. (2019). Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: Current trends. FUTURE MEDICINAL CHEMISTRY, 11(8), 901-921 [10.4155/fmc-2018-0380].
Fabini E.; Manoni E.; Ferroni C.; Del Rio A.; Bartolini M.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/726228
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 27
social impact